Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio Will Need Fundraise After Agreeing To Repay Part of Loan

Mon, 18th Feb 2019 09:27

LONDON (Alliance News) - Shares in Motif Bio PLC plunged on Monday as its subsidiary, Motif Biosciences Inc signed an amendment agreement with lender Hercules Capital Inc over a loan agreement in November 2017.

The new agreement requires Motif Biosciences to repay some of the loan and means Motif Bio will need to raise equity.

Shares in the antibiotics-focused biopharmaceutical company dropped 27% to 7.43 pence on Monday.

Under the amendment, Motif Biosciences will immediately repay USD7 million, and make a further repayment of USD500,000 within 90 days.

Motif Bio said it had agreed to the amendment to avoid any action by Hercules based on any position the lender may take that the company is in default.

Following the repayment, Motif Bio itself will have USD3 million in cash and USD7.7 million of debt drawn from the Hercules loan facility.

The company said it will now need to manage its funds "aggressively" and raise capital in the near term.

In November 2017, Motif Bio secured a USD20 million debt facility from Hercules to fund pre-commercialisation activities for the US launch of iclaprim in 2019.

In addition, Motif Bio is looking to set up a meeting with the US Food & Drug Administration after it rejected the company's new drug application for iclaprim on Thursday last week.

Iclaprim is a proposed treatment for acute bacterial skin and skin structure infections.

Motif Bio noted that the FDA normally grants a meeting within 30 to 45 days. However, there is no guarantee of the date of a meeting, nor that Motif Bio will have sufficient funds to allow it to reach this date.

"The company is currently assessing the options available to it to raise sufficient capital to provide cash runway to enable it to meet the FDA and discuss options to advance iclaprim towards approval," it said.

More News
14 Jun 2021 20:33

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

Read more
26 May 2021 21:28

IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million

IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million

Read more
26 May 2021 18:18

TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound

TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound

Read more
10 May 2021 15:52

IN BRIEF: Motif Bio 2020 loss narrows due to impairment in prior year

IN BRIEF: Motif Bio 2020 loss narrows due to impairment in prior year

Read more
29 Mar 2021 14:25

IN BRIEF: Motif Bio progresses reverse takeover, expects AIM return

IN BRIEF: Motif Bio progresses reverse takeover, expects AIM return

Read more
26 Feb 2021 20:20

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary

Read more
27 Jan 2021 14:37

IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy

IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy

Read more
5 Jan 2021 15:04

IN BRIEF: Motif Bio Advancing Process To Complete Reverse Takeover

IN BRIEF: Motif Bio Advancing Process To Complete Reverse Takeover

Read more
12 Oct 2020 11:50

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Read more
23 Sep 2020 16:13

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Sep 2020 14:08

IN BRIEF: Motif Bio Annual Pretax Loss Narrows Amid Takeover Hopes

IN BRIEF: Motif Bio Annual Pretax Loss Narrows Amid Takeover Hopes

Read more
29 Jul 2020 15:39

IN BRIEF: Motif Bio Shares Suspended; Still Hopes For Reverse Takeover

IN BRIEF: Motif Bio Shares Suspended; Still Hopes For Reverse Takeover

Read more
29 Jul 2020 09:59

Motif Bio shares suspended from trading

(Sharecast News) - Pharmaceutical company Motif Bio saw its shares suspended from trading on Wednesday in order to satisfy AIM rules.

Read more
23 Jun 2020 08:48

CORRECT: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

CORRECT: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

Read more
22 Jun 2020 14:14

IN BRIEF: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

IN BRIEF: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.